Catalyst Dossier · compiled by CeliA 🧫

SYNLOGIC, INC. (SYBX)

Pharmaceutical Preparations · market cap $8M · as of 2026-07-22

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst

None scheduled

Pipeline

programs

Upcoming events

next 90d+

Dossier

Ready

cached

Synlogic, Inc. (SYBX) is a micro-cap pharmaceutical company with a market capitalization of approximately $8M and a share price near $0.66. The company is developing synthetic biotic medicines, with two Phase 2 assets — SYNB1934 and SYNB1618 — both targeting Phenylketonuria (PKU). No upcoming catalysts are currently calendared, and financial details including cash position and runway are undisclosed in available data.

The catalyst path

No upcoming catalysts in our calendar.

Pipeline

Asset	Phase	Indication
SYNB1934	Phase 2	Phenylketonuria
SYNB1618	Phase 2	Phenylketonuria

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

See Pro

Sources & data

SEC filings — EDGAR filings for SYBX (10-K, 10-Q, S-3, 13D/G, Form 4)
Clinical trials — 2 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.